Premier Biomedical Recognized for Huge Growth Potential

One of Five Small Cap Stocks Mentioned as Possible Leaders in Their
Respective Fields

EL PASO, Texas–(BUSINESS WIRE)–Premier Biomedical, Inc.(OTCQB:
“BIEI”) a biotech research company focused on discovering,
developing, and commercializing medical treatments for a wide range of
diseases in humans, including innovative therapies for breast cancer,
announced today that Seraphim Strategies, LLC has named Premier
Biomedical, Inc. as one of five small cap stocks that they believed
could experience huge growth potential.

The report stated, “Another small cap with big aspirations is Premier
Biomedical (BIEI), Inc. (sic) The company focuses on new alternative
treatments for a wide range of diseases, with a special focus on breast
cancer and alternatives to chemotherapy. A scientist working closely
with the company and its resources was recently invited to present
findings at the San Antonio Breast Cancer symposium.”

You can read the entire article here.

William A. Hartman, President and CEO of Premier, said of the article,
“We are pleased that our potential is beginning to be recognized.
Besides our innovative, extracorporeal (outside the body) treatment for
blood borne-diseases, including breast cancer, we are working on
bringing relief to those suffering from fibromyalgia and neuropathic
pain with our patented drug, Feldetrex®, for which we plan on initiating
regulatory testing in the near future. We are in the process of
exploring joint ventures with established drug companies in other parts
of the world to bring these treatments to patients as quickly as
possible.” Contact William Hartman at 724-633-7033, PR@premierbiomedical.com.

About Premier Biomedical, Inc.

Premier
Biomedical, Inc. (OTCQB: BIEI)
is a research-based company that intends to discover and develop medical
treatments for a wide range of diseases in humans. Premier has obtained,
via license agreements, the technology behind multiple provisional
patents in the United States and a PCT Europe National Patent. Founded
in 2010, Premier has partnered with the Department of Defense with
Center of Expertise at the William Beaumont Army Medical Center. The
company’s R&D efforts are centered in El Paso, TX. The Company is a
fully-reporting issuer whose common stock trades on the OTCQB
marketplace maintained by OTC Markets Group, Inc. under the ticker
symbol “BIEI“.

For more information, please visit our website http://www.premierbiomedical.com/

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as
defined in the Private Securities Litigation Reform Act of 1995).
Premier Biomedical, Inc. cautions that statements, and assumptions made
in this news release constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are made.
These statements may address issues that involve significant risks,
uncertainties, estimates made by management. Actual results could differ
materially from current projections or implied results. Premier
Biomedical, Inc. undertakes no obligation to revise these statements
following the date of this news release.

Contacts

Premier Biomedical, Inc.
W. Hartman, 724-633-7033